{
  "emaEpar": [],
  "fdaDrugLabel": [
    {
      "brand": "ZEPZELCA",
      "indication": "1 INDICATIONS AND USAGE ZEPZELCA is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ZEPZELCA is an alkylating drug indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. ( 1 ) This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )",
      "manufacturer": "Jazz Pharmaceuticals, Inc.",
      "splSetId": "632bb50c-3bcb-4c85-9056-fc33410550ae"
    }
  ],
  "id": "Lurbinectedin",
  "nciThesaurus": {
    "casRegistry": "497871-47-3",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A synthetic tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity. Lurbinectedin covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death.",
    "fdaUniiCode": "2CN60TN6ZS",
    "identifier": "C82382",
    "preferredName": "Lurbinectedin",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C2115",
      "C25760"
    ],
    "synonyms": [
      "LURBINECTEDIN",
      "Lurbinectedin",
      "PM01183",
      "Zepzelca"
    ]
  }
}